Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Allon Therapeutics presents AL-108 human efficacy data at worlds leading Alzheimers disease conference
August 16th, 2008
A potential new treatment for Alzheimer's disease that reduces the classic Alzheimer's "tangle" pathology in mice has also improved specific memory function in humans with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer's disease, according to a presentation today at a news conference hosted by the Alzheimer's Association at their International Conference on Alzheimer's Disease and Related Disorders (ICAD 2008). Dr. Donald E. Schmechel, a Duke University geriatrics professor and the principal investigator of the clinical trial that evaluated drug candidate AL-108 in 144 aMCI patients, said the trial's results increase the importance of "tangles" in...
Source: Law & Health Weekly (2008-08-16)
|
